How much funding has EADERM raised?

EADERM has raised $3.2M in total funding, most recently a Series A round.

Who are EADERM's investors?

EADERM's investors include UntroD Capital, ANRI.

Where is EADERM headquartered?

EADERM is headquartered in Japan.

What industry is EADERM in?

EADERM operates in Biotech, Healthcare.

EADERM

Small molecule therapeutics targeting epithelial stem cell regeneration

Japan · $3.2M raised

Biotech

Healthcare

Employees: 1–10
Business Model: B2B
Website: eaderm.com

Total Funding: $3.2M
Last Round: $3.2M Series AJun 2025
Rounds: 1

About

EADERM (株式会社イーダーム) is a Japanese drug discovery biotechnology startup developing innovative small-molecule therapeutics based on tissue stem cell science, focused on skin and hair conditions. The company's proprietary platform targets epithelial stem cell protection and quality control mechanisms in vivo, enabling discovery of novel drug candidates for alopecia (hair loss), pressure ulcers (bedsores), and rare diseases such as progeria. EADERM's research and development pipeline aims to address disease mechanisms through stem cell regulation rather than symptomatic treatment. In July 2026, the company announced an exclusive evaluation and license option agreement with Rohto Pharmaceutical.

Summary

EADERM is a Biotech company based in Japan. It has raised $3.2M in total across 1 round, most recently a $3.2M Series A round in Jun 2025. Investors include UntroD Capital and ANRI.